14 September 2010
Syndromic Surveillance Experts Will Recommend Standards for Stage 1 Meaningful Use
Brighton, Massachusetts – The International Society for Disease Surveillance (ISDS), with the support of the Centers for Disease Control and Prevention’s BioSense Program has convened a Meaningful Use Workgroup to define current syndromic surveillance business standards and data requirements that best support Stage 1 meaningful use of electronic health record (EHR) technology by public health departments.
In this first project phase, the Workgroup will develop a provisional business process model (BPM), to inform minimum data specifications for syndrome-based public health surveillance.
An interim Stage 1 Meaningful Use recommendation for EHR vendors on syndromic surveillance data specifications will be released in October and will be ready for public comment starting in November.
A final Stage 1 Meaningful Use recommendation for syndromic surveillance will incorporate public comments and be released in January, 2011.
ISDS is coordinating this initiative with the Joint Public Health Informatics Taskforce (JPHIT). HLN Consulting, LLC (San Diego, CA), will provide analytic support to the workgroup.
ISDS’s Meaningful Use workgroup consists of seven expert syndromic surveillance practitioners from state and local public health authorities in Florida, Washington, Virginia, Indiana, Georgia, New York, and Boston, MA.
The International Society for Disease Surveillance works to improve population health by advancing the science and practice of surveillance to support timely and effective prevention and response. We facilitate interdisciplinary collaboration, and promote and conduct research, education, and advocacy.
Charles Ishikawa, M.S.P.H.